Results 11 to 20 of about 4,942 (259)

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol [PDF]

New England Journal of Medicine, 2020
BACKGROUND Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent dosing ...
Kausik K. Ray, R. Scott Wright, David Kallend, Wolfgang Köenig, Lawrence A. Leiter, Frederick J. Raal, Jenna A. Bisch, Tara Richardson, Mark Jaros, Peter Wijngaard, John J.P. Kastelein   +10 more
core   +5 more sources

Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin [PDF]

Frontiers in Pharmacology
BackgroundInclisiran is an siRNA-based cholesterol-lowering drug with N-acetylgalactosamine carbohydrate (GalNAc) and is used for the treatment of hypercholesterolemia or dyslipidemia.
Fei Li, Huan Ye, Lingbin Chen, Yuanchun Ma, Sunhui Chen   +4 more
doaj   +3 more sources

Relative Efficacy of Alirocumab, Evolocumab, Inclisiran, and Bempedoic Acid on Lipids in Patients with Cardiovascular Disease or Familial Hypercholesterolaemia. [PDF]

J Clin Med
Background: Lowering lipid levels after an acute coronary syndrome is critical for preventing recurrent adverse cardiovascular events. Multiple medications are now available, but there is limited evidence comparing how frequently they lead to the ...
Khattak S, Ochoa-Ferraro A, Khan N, George S, Khan SQ, Townend JN, Dawson C, Thomas MR.   +7 more
europepmc   +4 more sources

The Effects of Inclisiran on the Subclinical Inflammatory Markers of Atherosclerotic Cardiovascular Disease in Patients at High Cardiovascular Risk [PDF]

Pharmaceuticals
Background/Objectives: Hypercholesterolemia, accompanied by vascular inflammation, leads to the premature initiation and progression of atherosclerosis, and both are considered nowadays as well-established cardiovascular (CV) risk factors.
Mateusz Maligłówka, Adrianna Dec, Łukasz Bułdak, Bogusław Okopień   +3 more
doaj   +3 more sources

Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management [PDF]

BMC Cardiovascular Disorders
Background Inclisiran is a novel small interfering RNA therapeutic developed to lower lipid levels by targeting hepatic production of proprotein convertase subtilisin/kexin type 9.
Shakta Mani Satyam, Mohamed El-Tanani, Mohamed Anas Patni, Abdul Rehman, Sara Muhammad Irshad, Reem Raheem, Esha Junais, Ashika Anu John, Rena Yusuf Rassal, Rashmi Kumari, Sainath P   +10 more
doaj   +2 more sources

Real-World Adherence and Effectiveness of Inclisiran in Lowering LDL-C: Results from 1 Year of Follow-Up [PDF]

Cardiology and Therapy
Introduction Atherosclerotic cardiovascular disease (ASCVD) is a global health concern. Reducing low-density lipoprotein cholesterol (LDL-C) is critical in ASCVD prevention and treatment.
Christie M. Ballantyne, Timothy E. Graham, Lucinda J. Van Anglen, Bruce J. Iteld, Harvey Serota, Xiaoli Niu, Sean McElligott, Kelly E. Hanna, Tyler J. Varisco   +8 more
doaj   +2 more sources

Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin Intolerance. [PDF]

Eur J Neurol
Limited data exist on the efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and inclisiran among patients with neuromuscular disorders and statin‐induced myotoxicity and/or hepatotoxicity.
Theodorou A, Papagiannopoulou G, Akrivaki A, Fanouraki S, Moschovos C, Papadopoulou M, Palaiodimou L, Merkouri F, Melanis K, Salakou S, Kitsos D, Lambadiari V, Zouvelou V, Papadimas G, Giannopoulos S, Alexandrov AV, Tsivgoulis G.   +16 more
europepmc   +3 more sources

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia [PDF]

New England Journal of Medicine, 2020
Familial hypercholesterolemia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Monoclonal antibodies directed against proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to reduce LDL cholesterol levels by more than 50% but ...
Raal, Frederick J., Kallend, David, Ray, Kausik K., Turner, Traci, Koenig, Wolfgang, Wright, R. Scott, Wijngaard, Peter L.J., Curcio, Danielle, Jaros, Mark J., Leiter, Lawrence A., Kastelein, John J.P., ORION-9 Investigators,   +11 more
openaire   +6 more sources

Inclisiran in Dyslipidemia with High Residual Platelet Reactivity [PDF]

Diseases
Background: High residual platelet reactivity (HRPR) and persistent dyslipidemia remain important unmet needs in cardiovascular risk management, particularly in patients undergoing coronary revascularization.
Dina Kapsultanova, Sholpan Zhangelova, Friba Nurmukhammad, Zulfiya Makasheva, Orazbek Sakhov, Tamara Galkina, Farida Rustamova, Dana Akhmentayeva, Botakoz Aubakirova   +8 more
doaj   +2 more sources

Inclisiran, ARN interferente pequeño: un nuevo enfoque para el tratamiento del colesterol [PDF]

Revista Colombiana de Cardiología, 2022
La hiperlipidemia es altamente prevalente y contribuye de forma sustancial a la enfermedad cardiovascular aterosclerótica, que es una de las principales causas de morbilidad y mortalidad en Colombia.
Maria C. Fragozo-Ramos, Valeria Gómez-Sierra, Laura V. Gómez-Galvis, Rafael Campo, Raúl D. Santos, Alejandro Román-González   +5 more
doaj   +2 more sources